The UCLA-Community Breast Cancer Collaborative Clinical Translational Research Program
Annual rept. 28 Sep 2001-27 Sep 2002
CALIFORNIA UNIV LOS ANGELES
Pagination or Media Count:
Breast cancer remains a serious disease in the United States. Recently, advances in molecular and cell biology have identified specific targets and strategies for the treatment and prevention of breast cancer. The rapid translation of these advances into clinical trials is imperative for three reasons. First, some of these strategies will be effective in decreasing the incidence, morbidity, or mortality of breast cancer. The more rapidly women enter the clinic, the more they will benefit. Second, patients with breast cancer desire and deserve access to these novel treatments, particularly when standard approaches have been exhausted. Finally, clinical trials provide information that compliments basic research and advances the understanding of the disease. The majority of patients with breast cancer are cared for in the community. Although many community physicians are committed to advancing the field, the infrastructure to support translational trials of novel treatment or prevention strategies does not exist in the community setting. Moreover, few academic cancer centers have forged meaningful partnerships with consortia of community physicians to provide them with the laboratory interface and statistical and regulatory support required for good translational clinical research.
- Medicine and Medical Research